Protalix BioTherapeutics, Inc. (PLX) Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Protalix BioTherapeutics, Inc. NYSE:PLX Healthcare · Biotechnology
Mkt Cap $255.91M
EV -
SI 4.3%
Net Cash/Sh -
Prev close $3.02 -1.66%Open $2.97 +2.19%Now $3.04 VOL 1.16M $ Vol $3.56M RVOL 1.18x
Mkt Cap $255.91M
EV -
VOL 1.16M sh
$ Vol $3.56M
RVOL 1.18×
SI 4.3%
Net Cash/Sh -
Press Release
Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results
Protalix reported Q3 2026 revenue of $21.9 million, up ~23% year-over-year, with net income of $4.0 million ($0.05 per share) versus $2.4 million a year ago. Year-to-date revenue reached $75.6 million versus $43.6 million, driven largely by a $25.0 million Chiesi milestone tied to the EU approval of Elfabrio's every-four-weeks dosing; goods revenue also rose on higher Chiesi sales, partially offset by lower Pfizer and Fiocruz purchases. Management reaffirmed 2026 guidance of $78-83 million in total revenues and said it expects to meet or exceed the range, ending September with $48.5 million in cash and deposits and no debt or warrants.
• 9d ago AI analysis › Press Release ● Major
Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200
globenewswire.com • 10d ago Press Release
Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations
Protalix presented new individual-patient PK/PD data at ACR Convergence 2026 showing that higher single doses of PRX-115 kept plasma uric acid below the 6.0 mg/dL therapeutic target for extended periods. At the 36 mg dose, mean uric acid stayed below target for up to 12 weeks after a single infusion, with PRX-115 plasma levels remaining measurable for up to 85 days, supporting less frequent dosing.
• 10d ago AI analysis › Press Release
Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026
Protalix BioTherapeutics will release its third quarter 2026 financial results and provide a business update on November 10, 2026, with a conference call and webcast at 8:00 a.m. ET. The notice contains no financial figures or operational news; it is a scheduling announcement only.
• 16d ago AI analysis › Press Release
Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare Conference
Protalix BioTherapeutics announced that CEO Dror Bashan will present a live corporate overview at the Stifel 2026 Healthcare Conference on November 10, 2026, in New York City. Management will also hold one-on-one meetings with registered investors, and a webcast plus archived replay will be available.
• 24d ago AI analysis › Press Release
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
Protalix BioTherapeutics announced that CFO Gilad Mamlok will participate in two investor conferences in New York City in September 2026. The company presents at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026 at 2:00 p.m. EDT, and joins a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026 at 1:05 p.m.
• 2mo ago AI analysis › Press Release ● Major
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
Protalix reported Q2 2026 revenue from selling goods of $19.8 million, up from the prior year, with total year-to-date revenue climbing to $53.6 million driven by Elfabrio sales and a $25.0 million milestone payment from Chiesi. The company achieved year-to-date profitability with a net income of $22.1 million, reversing a net loss of $3.5 million in the same period of 2025.
• 3mo ago AI analysis › Press Release
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
Protalix BioTherapeutics announced it will release its second quarter 2026 financial results and provide a business update on August 12, 2026. Management will host a conference call at 8:00 a.m. Eastern Time to discuss the financial results and recent corporate and regulatory developments.
• 3mo ago AI analysis › Press Release ● Major
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
prnewswire.com • 6mo ago Press Release
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
Protalix BioTherapeutics announced it will release Q1 2026 financial results on May 13, 2026, before market open. Management will host a conference call at 8:00 a.m. EDT to discuss results and provide updates on corporate and regulatory developments.
• 6mo ago AI analysis › Press Release
REG-DISCLOSURE FISCAL 2026/26 OF TRANSACTIONS ON TREASURY SHARES
Pluxee N.V. disclosed the execution of treasury share transactions (buybacks) from April 27 to April 30, 2026. Over the four-day period, the company repurchased a total of 207,573 shares across multiple trading platforms (XPAR, DXE, TQE) at an approximate average price of €12.10.
• 6mo ago AI analysis › Press Release
REG-DISCLOSURE FISCAL 2026/25 OF TRANSACTIONS ON TREASURY SHARES
Pluxee N.V. disclosed its transactions on treasury shares for the period from April 20 to April 24, 2026. The company repurchased shares daily across the XPAR, DXE, and TQE platforms, with daily volumes totaling between 50,000 and 54,000 shares.
• 6mo ago AI analysis ›